Clene Inc. (CLNN) News
Follow Clene Inc. (CLNN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Clene Reports Third-Quarter Revenue of $56,000
EQUITY | Nov 04, 2026, 01:43 PM UTC
M
Clene Reports $3.9M Q3 Net Income, Cash Runway Through Mid-Q1 2027
Clene reported Q3 2026 net income of $3.9 million, compared with an $8.8 million net loss a year earlier. Cash stood at $9.9 million on Sept. 30, 2026; the company expects its runway to extend through mid-Q1 2027.
EARNINGS | Nov 04, 2026, 01:41 PM UTC
M
Clene Posts Q3 Profit on Warrant Liability Gains
EQUITY | Nov 04, 2026, 01:37 PM UTC
M
Clene Swings to Q3 Net Profit of $3.92 Million
EQUITY | Nov 04, 2026, 01:37 PM UTC
M
Clene Reports Q3 Pretax Profit of USD 3.915 Million
EQUITY | Nov 04, 2026, 01:32 PM UTC
M
Clene Reports Third-Quarter 2026 Financial Results and Operating Highlights
Clene said it submitted a New Drug Application to the FDA in October; the supplied body is truncated and does not provide further financial results.
EQUITY | Nov 04, 2026, 01:31 PM UTC
L
Clene reports third-quarter net income of $3.92 million
EARNINGS | Nov 04, 2026, 01:31 PM UTC
L
Clene submits CNM-Au8 new drug application to FDA for ALS
Clene announced submission of a new drug application to the FDA for CNM-Au8, intended to treat ALS.
REGULATION | Oct 19, 2026, 12:00 PM UTC
L
CLNN - Clene to Present at Upcoming Investor Conferences
CLNN - Clene to Present at Upcoming Investor Conferences
NEWS | Sep 22, 2026, 12:00 PM UTC
L
CLNN - Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
CLNN - Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
REGULATION | Sep 21, 2026, 12:30 PM UTC
L
CLNN - Clene Announces $4 Million Registered Direct Offering
CLNN - Clene Announces $4 Million Registered Direct Offering
NEWS | Sep 15, 2026, 01:01 PM UTC
M
CLNN oral nanotherapeutic for ALS nears NDA submission
CLNN is advancing an oral nanotherapeutic for ALS, citing consistent neurofilament reduction and survival benefits in trials. The company says an NDA submission is imminent, with a confirmatory Phase III and targeted com
EQUITY | Sep 09, 2026, 02:35 PM UTC
L
CLNN nears NDA submission for ALS nanotherapeutic
CLNN says an ALS nanotherapeutic is nearing NDA submission after clinical survival and neurofilament light benefits, with a strong safety profile. Regulatory review is expected to begin soon, with commercialization targe
EQUITY | Sep 09, 2026, 02:05 PM UTC
L
Clene management to present at September investor conferences
Clene Inc. said management will present at the 2026 Cantor Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
CLNN - Clene to Present at Upcoming September Investor Conferences
CLNN - Clene to Present at Upcoming September Investor Conferences
EQUITY | Sep 03, 2026, 12:00 PM UTC
L
Clene (CLNN) to Present at Emerging Growth Conference
Clene (CLNN) says it will present at the Emerging Growth Conference, with no additional details on topics or timing provided in the feed.
EQUITY | Aug 17, 2026, 12:30 PM UTC
L
Clene reports Q2 2026 financial results and operating highlights
Clene (CLNN) reports its second quarter 2026 financial results along with recent operating highlights, per the company’s release.
EARNINGS | Aug 14, 2026, 12:30 PM UTC
L
CLNN to present at Canaccord conference
CLNN presents at conference
EQUITY | Jul 29, 2026, 12:30 PM UTC